Gastric lanthanosis (lanthanum deposition) in dialysis patients treated with lanthanum carbonate

Encephalopathy in a dialysis patient treated with lanthanum carbonate (LC)

Sir, Dr Fraile et al. [1] report the interesting case of a dialysis patient who was treated with lanthanum carbonate (LC; 2000 mg daily for 8 months increased to 3500 mg daily for the subsequent 10 months) and developed acute confusional syndrome. Conduct disorders and delirious ideas were also observed. The neurological examination was normal and the electroencephalogram tracing, as well as br...

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate

Hyperphosphatemia is an inevitable consequence of end stage chronic kidney disease and is present in the majority of dialysis patients. Recent observational data has associated hyperphosphatemia with increased cardiovascular mortality among dialysis patients. Dietary restriction of phosphate and current dialysis prescription practices are not enough to maintain serum phosphate levels within the...

Lanthanum deposition in a dialysis patient.

Lanthanum carbonate (LaCO(3)) is an oral phosphate binder widely used in end-stage renal disease (ESRD). Preclinical animal studies reported the highest La concentrations outside the gut to be in mesenteric lymph nodes. We observed previously unreported La deposition visible by light microscopy and confirmed by scanning electron microscopy with energy dispersive x-ray spectroscopy in a mesenter...

Lanthanum carbonate

Encephalopathy caused by lanthanum carbonate

Lanthanum carbonate is a nonaluminum, noncalcium phosphate-binding agent, which is widely used in patients with end-stage chronic kidney disease. Until now, no significant side-effects have been described for the clinical use of lanthanum carbonate, and there are no available clinical data regarding its tissue stores. Here we report the case of a 59-year-old patient who was admitted with confus...